SYRE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Spyre Therapeutics Inc (SYRE) is not a strong buy for a beginner investor with a long-term strategy at this moment. While the stock has positive technical indicators and strong analyst ratings, the company's financial performance shows significant losses, and there are no recent news catalysts or trading signals to support immediate action. The investor may consider monitoring the stock for future opportunities.
The stock shows bullish momentum with MACD histogram above 0 and expanding positively. The RSI is neutral at 75.812, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key resistance levels are at 37.48 and 39.076, with support at 32.314 and 30.718.
Strong analyst ratings with price targets of $53 and $64, citing significant potential in the company's monoclonal antibody pipeline and autoimmune disease programs. Technical indicators suggest bullish momentum.
The company's financial performance in Q3 2025 shows no revenue growth, a significant drop in net income (-83.80% YoY), and a decline in EPS (-86.03% YoY). No recent news or congress trading data to act as a catalyst.
In Q3 2025, the company reported no revenue growth, a net income loss of -$11.18M (down 83.80% YoY), and EPS dropped to -0.19 (down 86.03% YoY). Gross margin remains at 0.
Mizuho and Citi initiated coverage with Outperform and Buy ratings, respectively, and price targets of $53 and $64. Both firms see significant potential in the company's pipeline and future data readouts in 2026-2027.
